TREATMENT OF MULTIPLE SCLEROSIS (MS) Russian patent published in 2016 - IPC A61K39/395 

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of medicine and is intended for treatment of multiple sclerosis (MS). Claimed is method of treating multiple sclerosis (MS) in patient who was first treated by means of MS-therapy with drugs different from alemtuzumab, including introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as initial treatment course and at least 3 months after initial treatment course introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method for reducing number of lymphocytes in patient with multiple sclerosis (MS), with said patient first being treated by means of MS-therapy with medications different from alemtuzumab, including introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as initial treatment course and at least 3 months after initial treatment course introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method of reducing risk of recurrence or risk of development of clinically significant disability in patients with multiple sclerosis, with said patient first being treated by means of MS-therapy with medications different from alemtuzumab, including introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as initial treatment course at least 3 months after initial treatment course introduction of 1-12 mg/day of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method of treating multiple sclerosis (MS) in patient who was first treated by means of MS-therapy with drugs different from alemtuzumab, including introduction of 10-60 mg of alemtuzumab to patient for 1-5 days as initial treatment course and at least 3 months after initial treatment course introduction of 10-60 mg of alemtuzumab to patient for 1-5 days as second treatment course. Claimed is method for treating recurrences of multiple sclerosis (MS) in patient who first was treated by means of MS-therapywith medications which are different from alemtuzumab, including introduction of 12 mg/day of alemtuzumab to patient for 5 successive days as initial treatment course and introduction of 12 mg/day after 12 months of alemtuzumab to patient for three successive days as second treatment course, where 12 mg of alemtuzumab for each treatment cycle are introduced to patient by intravenous infusion for 4-hour time period, and where patient immediately before treatment with alemtuzumab, which is introduced for first three days of each treatment cycle, is preliminarily treated by means of steroids.

EFFECT: claimed group of inventions is highly effective for treatment of multiple sclerosis.

23 cl, 3 dwg, 5 ex